Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type
: j) E8 y1 K$ r) ~) F/ aNOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
( ] k" k4 }5 q8 S' Z5 ?* Q9 q+ Author Affiliations* \# Q) r5 r8 F* B( i
( P* E) v; |+ [9 w7 O6 o
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan
3 k; r/ E& h5 D) e) L2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan $ B$ G# V" @: H5 T% e ^
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan
( j4 Y& G& i& x Q4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
# z, P; v) [0 B: i5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan 9 ]$ p+ o, a8 t/ C) h% x, L
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan ; b1 Z1 I9 D; u$ P0 V! ?" N$ B
7Kinki University School of Medicine, Osaka 589-8511, Japan # n( |4 b8 w. E& D0 v9 t9 u
8Izumi Municipal Hospital, Osaka 594-0071, Japan 9 E- O! K) t9 Z! z& f% ~
9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan 6 ^4 |; a1 Z3 B- N) e+ S1 a
Correspondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp 6 }, q! L- d) Z2 l3 W
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type. . M& S- Q& A2 L3 F! X! g8 N: ^2 o6 _
9 E; G4 N2 B2 N2 }( X' B/ h5 t
|